Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO OTCMKTS:BPMUF OTCMKTS:EMIS NASDAQ:FIXX NASDAQ:FLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$51.57-0.8%$49.59$21.34▼$58.40$4.15B-0.151.06 million shs618,863 shsBPMUFBasilea Pharmaceutica$61.34$53.46$47.50▼$61.34$807.83M0.290 shsN/AEMISEmisphere Technologies$7.81$7.81$4.06▼$9.16N/AN/AN/AN/AFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsFLXNFlexion Therapeutics$24.96-0.2%$9.20$4.30▼$13.66$1.26B1.531.18 million shs2 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.83%-0.85%-2.62%+44.58%+114.88%BPMUFBasilea Pharmaceutica0.00%0.00%+6.31%+13.59%+27.39%EMISEmisphere Technologies0.00%0.00%0.00%0.00%0.00%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%FLXNFlexion Therapeutics-0.03%-0.24%+174.34%+174.34%+174.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.396 of 5 stars3.51.00.04.71.40.80.0BPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AFIXXHomology Medicines0.6597 of 5 stars0.00.00.04.80.60.80.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5059.98% UpsideBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/AEMISEmisphere Technologies 0.00N/AN/AN/AFIXXHomology Medicines 0.00N/AN/AN/AFLXNFlexion Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BPMUF, FIXX, FLXN, AKRO, and EMIS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ABPMUFBasilea Pharmaceutica$236.92M3.41$6.85 per share8.96$6.99 per share8.78EMISEmisphere TechnologiesN/AN/AN/AN/AN/AN/AFIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00FLXNFlexion Therapeutics$85.55M14.68N/AN/A($0.34) per share-73.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)BPMUFBasilea Pharmaceutica$88.14MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)EMISEmisphere TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ALatest BPMUF, FIXX, FLXN, AKRO, and EMIS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AEMISEmisphere TechnologiesN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80BPMUFBasilea Pharmaceutica1.184.854.16EMISEmisphere TechnologiesN/AN/AN/AFIXXHomology MedicinesN/A7.257.25FLXNFlexion TherapeuticsN/A4.384.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ABPMUFBasilea PharmaceuticaN/AEMISEmisphere TechnologiesN/AFIXXHomology Medicines31.32%FLXNFlexion Therapeutics90.01%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%BPMUFBasilea PharmaceuticaN/AEMISEmisphere Technologies72.90%FIXXHomology Medicines16.10%FLXNFlexion Therapeutics9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableEMISEmisphere Technologies6N/AN/ANot OptionableFIXXHomology Medicines758.13 million48.77 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataBPMUF, FIXX, FLXN, AKRO, and EMIS HeadlinesRecent News About These CompaniesWar Robots is coming to alternative storefronts following MY.GAMES and Flexion's collaborationOctober 3, 2024 | pocketgamer.comPFlexion wins contract to support CFPB in evaluating financial education contentApril 25, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 19, 2024 | finance.yahoo.comFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 11, 2024 | tmcnet.comVIRI Virios Therapeutics, Inc.April 6, 2024 | seekingalpha.comSpyre Therapeutics Inc SYREFebruary 14, 2024 | morningstar.comMPFIZER INC's Net WorthFebruary 10, 2024 | benzinga.comFlexion/Extension Fluoroscopy of C-Spine is InadequateJanuary 12, 2024 | medscape.comMSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comFlexion Mobile: Cuts 2023 sales forecast on softer Q3 - ABGNovember 6, 2023 | nyheter24.seNOppo Unveils Find N3: Foldable Phone with Flexion Hinge and Snapdragon 8 Gen 2October 19, 2023 | newsd.inNFlexion wins MCADS contract to modernize CMS Claims Handling SystemJuly 11, 2023 | benzinga.comFlexion achieves Select Tier Status within the AWS Partner NetworkJuly 10, 2023 | finance.yahoo.com7 Exercises to Stretch Plantar Flexion MovementJune 10, 2023 | yahoo.comPain Therapeutics conference is taking place in London next weekJune 8, 2023 | pharmaphorum.comPFlexion Mobile: Notice of Annual General MeetingMay 31, 2023 | privataaffarer.seP2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 PagesMay 16, 2023 | marketwatch.comOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone ExperienceMay 4, 2023 | finance.yahoo.comProne Leg Flexion Trainers Market Global Outlook and Projection till 2029April 28, 2023 | marketwatch.comAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028April 12, 2023 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPMUF, FIXX, FLXN, AKRO, and EMIS Company DescriptionsAkero Therapeutics NASDAQ:AKRO$51.57 -0.43 (-0.83%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$51.53 -0.04 (-0.08%) As of 07/11/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Basilea Pharmaceutica OTCMKTS:BPMUF$61.34 0.00 (0.00%) As of 07/10/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Emisphere Technologies OTCMKTS:EMIS$7.81 0.00 (0.00%) As of 12/9/2020Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
